<DOC>
	<DOC>NCT00979134</DOC>
	<brief_summary>This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.</brief_summary>
	<brief_title>Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Minimum life expectancy of 12 weeks The presence of a solid, malignant tumour that is resistance to standard therapies or for which no standard therapies exist In the expansion for the study patients must have a tumour at least 1cm in size that can be measure using a CT or MRI scan, and provide a tumour sample to the sponsor company for testing of FGFR1 and/or 2 amplification Expansion, 5 groups of advanced cancer Solid tumours,FGFR1 and/or FGFR2 gene amplified Squamous NSCLC, FGFR1 gene low &amp; high amplified Gastric adenocarcinoma, including the lower oesophagus/gastrooesophageal junction, FGFR2 gene low &amp; high amplified Aged at least 25 years Treatment with any other chemotherapy, immunotherapy or anticancer agents within 3 weeks before the first dose of study An inability to be able to take the study medication A bad reaction to AZD4547 or any drugs similar to it in structure or class.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Advanced Solid Malignancies</keyword>
	<keyword>FGFR</keyword>
	<keyword>Squamous NSCLC</keyword>
	<keyword>Gastric adenocarcinoma</keyword>
</DOC>